구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Up-Titration (Patritumab Deruxtecan, Patritumab Deruxtecan (Up-Titration)) Daiichi Sankyo Co., Ltd.·Non-Small Cell Lung Cancer Metasta… 148 trials |
|---|---|
Overview Program | Patritumab Deruxtecan (Up-Titration) |
Overview Company | Daiichi Sankyo Co., Ltd. |
Overview Modality | ADC |
Overview Target | Non-Small Cell Lung Cancer Metastatic |
Overview Indication | Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Payload | deruxtecan, sacituzumab govitecan, brentuximabvedo |
Technology Linker | linker technologies, and targets to expand the applicability of ADCs across broader NS |
MoA Mechanism | antibody drug conjugated-induced nausea and vomiting (ADCINV) in patients with cancer |
MoA Biomarker | biomarkers will give new insights on individual MTX metabolism and drug adherence |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | tumour growth inhibition |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Alpha2 agonists for sedation to produce better outcomes for adults with critical illness: a synopsis of the A2B RCT with cost-effectiveness and process evaluation.. Most mechanically ventilated intensive care unit patients require sedation and analgesia for comfort. Current usual care is propofol-based sedation plus an opioid analgesic. The alpha2 agonists dexmedetomidine and clonidine are potenti… |
Clinical Safety signal | Alpha2 agonists for sedation to produce better outcomes for adults with critical illness: a synopsis of the A2B RCT with cost-effectiveness and process evaluation.. Most mechanically ventilated intensive care unit patients require sedation and analgesia for comfort. Current usual care is propofol-based sedation plus an opioid analgesic. The alpha2 agonists dexmedetomidine and clonidine are potenti… |
Clinical Selected reported efficacy | ORR 64% |
Clinical Reported ORR | 56% |
Clinical Reported PFS | 5.5 |
Clinical Result source | ClinicalTrials.gov NCT04619004 |
Clinical Program phase | PHASE_2 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT04619004 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Up-Titration (Patritumab Deruxtecan, Patritumab Deruxtecan (Up-Titration)) Daiichi Sankyo Co., Ltd.·Non-Small Cell Lung Cancer Metasta… 148 trials |
|---|---|
Overview Program | Patritumab Deruxtecan (Up-Titration) |
Overview Company | Daiichi Sankyo Co., Ltd. |
Overview Modality | ADC |
Overview Target | Non-Small Cell Lung Cancer Metastatic |
Overview Indication | Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Payload | deruxtecan, sacituzumab govitecan, brentuximabvedo |
Technology Linker | linker technologies, and targets to expand the applicability of ADCs across broader NS |
MoA Mechanism | antibody drug conjugated-induced nausea and vomiting (ADCINV) in patients with cancer |
MoA Biomarker | biomarkers will give new insights on individual MTX metabolism and drug adherence |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | tumour growth inhibition |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Alpha2 agonists for sedation to produce better outcomes for adults with critical illness: a synopsis of the A2B RCT with cost-effectiveness and process evaluation.. Most mechanically ventilated intensive care unit patients require sedation and analgesia for comfort. Current usual care is propofol-based sedation plus an opioid analgesic. The alpha2 agonists dexmedetomidine and clonidine are potenti… |
Clinical Safety signal | Alpha2 agonists for sedation to produce better outcomes for adults with critical illness: a synopsis of the A2B RCT with cost-effectiveness and process evaluation.. Most mechanically ventilated intensive care unit patients require sedation and analgesia for comfort. Current usual care is propofol-based sedation plus an opioid analgesic. The alpha2 agonists dexmedetomidine and clonidine are potenti… |
Clinical Selected reported efficacy | ORR 64% |
Clinical Reported ORR | 56% |
Clinical Reported PFS | 5.5 |
Clinical Result source | ClinicalTrials.gov NCT04619004 |
Clinical Program phase | PHASE_2 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT04619004 |
추천 비교
추천 비교